Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2013. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, rather than a comprehensive financial report.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to a specific share transaction:
- Share Purchase Price: 1612.44 pence per share.
- Transaction Date: April 16, 2013.
- Shares Acquired: 28,601 Ordinary Shares.
Material Changes
The filing details an increase in the shareholding of a connected person, Mrs. K Thomson, following the re-investment of a dividend paid to shareholders on April 11, 2013. No material changes to the company's overall financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is strictly a regulatory disclosure of a connected person's transaction in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
Key Facts for Investor Verification
- Verify the total dividend reinvestment program details for the April 11, 2013 payment date.
- Confirm the total shareholding of Mrs. K Thomson post-transaction.
- Note that this filing does not contain quarterly or annual financial performance data.